Vitamin D3 treatment differentially affects anxiety-like behavior in the old ovariectomized female rats and old ovariectomized female rats treated with low dose of 17β-estradiol
- 161 Downloads
Estrogen deficiency effects on affective-related behavior are restricted to certain periods of age after ovary removal. Among other nutraceuticals, one of such «natural» substances for treatment of affective-related diseases could be vitamin D3. It is a great interest to evaluate the effects of repeated cholecalciferol administration on anxiety-related behavior in the old female rats with long-term estrogen deficiency. The present study was performed to determine the behavioral effects of cholecalciferol treatment at different doses as an adjunctive therapy alone or in a combination with low dose of 17β-estradiol on anxiety-like behavior of the old (16–18 months) female rats at 12 weeks after ovariectomy.
Vitamin D3 supplementation individually (as cholecalciferol at doses of 1.0, 2.5 or 5.0 mg/kg/day, s.c.) or in co-administration with of 17β-estradiol (17β-E2, 0.5 μg/rat, s.c.) were given to the old ovariectomized (OVX) rats at 12 weeks after ovariectomy. Anxiety-related state was tested in the elevated plus maze (EPM) and light-dark test (LDT), as well behavioral reactivity was registered in the open field test (OFT). Moreover, 25-hydroxyvitamin D3 levels in the blood serum of these OVX rats treated with Vitamin D3 or Vitamin D3 plus 17β-E2 were measured.
The results of the present study indicated that Vitamin D3 supplementation at dose of 1.0 mg/kg/day decreased manifestations of anxiety-like profile in the old OVX rats. Treatment with Vitamin D3 (1.0 mg/kg/day) plus 17β-E2 in resulted in more profound anxiolytic-like effects the old OVX rats than effects of both drugs administered alone. Moreover, treatment with cholecalciferol (1.0 mg/kg/day, s.c.) in the old ovariectomized rats after ovariectomy at 12 weeks produced elevated estradiol and 25-OH-VD3 levels for these rats as compared to the old OVX females treated with oil solvent.
Using the preclinical study, chronic cholecalciferol, 17β-E2 and their combination treatment were shown to be effective for anxiety-like treatment in the old subjects with long-term estrogen deficiency.
KeywordsVitamin D3 Anxiety Menopause Estradiol Age Old female rats
Anxiety disorders are twice common in women than in men and the risk is increased during the menopausal transition more [1, 2]. Menopause is a phase of a woman’s life which indicates termination of her reproductive function. It is induced by the loss of ovarian follicular activity, which leads to the permanent cessation of menstruation [2, 3]. Menopause is often associated with an onset of mood disturbances, especially anxiety and depression [3, 4]. For women, data suggest that estrogens are strongly implicated in the regulation of mood and behavior, as well as in the pathophysiology of mood disorders [5, 6, 7]. Nowadays, there is a strong tendency to rising of duration of living in the whole world, however, the median age of programmed termination of a woman’s reproductive life failed to altered [5, 6, 7]. Thus, majority of women in the ageing population stays for a significant period of their lifetime in a postmenopausal state which is clearly associated with very low estrogen levels that could one of the marked trigger factors for development of affective-related disorders [5, 7].
A strategy to alleviate the mood disorders associated with menopause is hormonal replacement therapy (HRT) . However, controversial results related to the effectiveness of such treatment have been frequently reported . These discrepancies could be associated to various factors, one of them being the time when estrogen restitution is initiated after the beginning of menopause [10, 11].
There is growing interest about the potential of diet and nutrients to improve the mental health of the women population and for the treatment of psychiatric disorders [10, 11]. In the case of mood disorders, the limitations of psychotropic drugs to achieve adequate rates of clinical remission and functional recovery have promoted the search for complementary approaches [12, 13, 14, 15]. Menopausal women are now choosing to take alternative and complementary therapies marketed as «natural» treatments that offer the positive health effects of estrogens without the unwanted side effects [12, 13]. Effectiveness of α-tocopherol, ascorbic acid, β-carotene were previously shown for wide group of disorders and forms of administration [16, 17]. Among other nutraceuticals, one of such «natural» substances for treatment of affective-related diseases could be vitamin D (VD) [14, 15].
VD is a neuroactive secosteroid with well-known physiological role in skeleton formation and maintenance, as well as diverse «non-skeletal» functions [18, 19]. «Non-skeletal» functions of VD are connected with its different range of outcomes in the central nervous system, such as neuroplasticity, apoptosis, cell proliferation and differentiation [20, 21]. All functions of VD in the body (classical functions, i.e., effect upon calcium-phosphate management and the non-classical ones) are imposed by the VD nuclear receptor (VDR), regulating directly the gene expression [22, 23]. Nuclear VDR are member of receptors family for transcription factors which are activated by numerous ligands [22, 23]. VDR are present in most tissues and cells in the body, and within the brain show some specificity to the prefrontal cortex, hippocampus, cingulate gyrus, thalamus, hypothalamus and substantia nigra . This is of relevance as many of those brain regions have been implicated in the physiology of affective-related disorders.
Estrogen deficiency effects on affective-related behavior are restricted to certain periods of age after ovary removal [25, 26, 27]. Preclinical data suggest that onset age of menopause can be important to obtain behavioral positive or negative results. Thus, it is a great interest to evaluate the effects of repeated cholecalciferol administration on anxiety-related behavior in the middle-aged and old female rats with long-term estrogen deficiency.
The aim of the present study was to determine if repeated systemic treatment with cholecalciferol affected on anxiety-like behavior in the old female rats after long-term ovariectomy.
Female albino Wistar rats (16–18 months, old rats, weighing 260–270 g, respectively) from the special biocollection of Koltushi vivarium (St. Petersburg, Russia) were used in the present study. All rats were allocated in groups and were allowed to accommodate for 1 week in the animal house at I.P. Pavlov Institute of Physiology, of the Russian Academy of Sciences, before subjecting them to behavioral testing and pharmacological treatments. They were provided with a standard pellet diet and were given water ad libitum. The animals were kept at a temperature of 23 °C ± 2 °C and a 12 h light/dark cycle as well as a constant relative humidity (50% ± 10%) during all experimental sessions. Female rats of different age rats were randomly separated into experimental groups 4, including the control groups.
Vitamin D3 and 17β-E2 treatments, as well as anxiety-related tests were carried out a double-blind method by using rules of the Health guide for the care and use of Laboratory animals (1978) formulated by the National Institute of Health. Females of different age were placed to the special room for behavioral trials at least 1 h prior to the beginning of the experimental sessions which were performed from 09:00 am to 12:00 am. The experimental protocols of this study were approved by the Institutional Animal Ethics Committee of I.P. Pavlov Institute of Physiology, Russia (protocol 1095/1 from June 25, 2012).
Long-term ovariectomy surgery was performed as previously described . Briefly, middle-aged and old female rats were anesthetized with ketamine (70 mg/kg b.w.) mixed with xylazine (10 mg/kg b.w.). To avoid inflammation, the rats were administered with meloxicam (1 mg/kg b.w.). The fallopian tube was crushed and the ovary was removed by cutting. The effectiveness of long-term ovariectomy or 17β-estradiol (17β-E2) application was assessed by vaginal smears. The old ovariectomized (OVX) females were housed in groups of five in cages separated by groups. To assure the long-term absence of estrogens, all rats after surgery were remained to the housing facilities for 12 weeks.
17β-Estradiol, 17β-E2 (Sigma, USA) at low dose of 5.0 μg/rat [27, 28] and Vitamin D3 as cholecalcirefol (Sigma, USA) at several doses (1.0, 2.5 or 5.0 mg/kg)  were subcutaneously (s.c.) administered once daily starting 14 days prior to the cognitive experiments. 17β-E2 was dissolved in sterile sesame oil, VD3 – in 95% ethanol solvent, aliquoted and stored at -80 °C. The stock of VD3 was dissolved in a sterile water, resulting in a solution of cholecalciferol with 2% ethanol. All drug solutions were freshly prepared before each behavioral testing. 17β-E2 and cholecalcirefol were injected in a volume of 0.1 ml. The estrogen, 17β-E2 (E-8875, Sigma Chemical Co., St. Louis, MO, USA) was dissolved in sterile sesame oil. Cholecalcirefol (C-9756, Sigma Chemical Co., St. Louis, MO, USA) was dissolved in 95% ethanol, aliquoted and stored at -80 °C. The stock of cholecalciferol was diluted in a sterile water, resulting in a solution of cholecalciferol with 2% ethanol. 17β-E2 was injected subcutaneously (s.c. at a dose of 0.5 μg/rat). The low dose of 17β-E2 (5.0 μg/rat subcutaneously, s.c.) was chosen from the studies performed by Estrada-Camarena and co-workers [29, 30]. Three doses of cholecalciferol (1.0, 2.5 or 5.0 mg/kg, s.c.) were chosen from the behavioral study performed by Idrus and co-workers . All solutions were freshly prepared before each experimental series. All preparations were administered in a volume of 0.1 ml. Following 12 weeks after ovariectomy, cholecalciferol, 17β-E2 and oil solvent were injected once daily for 14 days.
Female rats (old intact and OVX) were randomly divided into 24 groups, accordingly to their age, with 8 rats in each group.
old intact female rats + solvent,
old intact female rats + cholecalciferol 1.0 mg/kg (old intact-Vit D3 1.0),
old intact female rats + cholecalciferol 2.5 mg/kg (old intact-Vit D32.5),
old intact female rats + cholecalciferol 5.0 mg/kg (old intact-Vit D3 5.0),
old OVX + solvent (old OVX-Sol),
old OVX rats +17β-E2 (old OVX-17β-E2),
old OVX rats + cholecalciferol 1.0 mg/kg (old OVX-Vit D3 1.0),
old OVX rats + cholecalciferol 2.5 mg/kg (old OVX-Vit D3 2.5),
old OVX rats + Vit D3 5.0 mg/kg (old OVX-Vit D3 5.0),
old OVX rats + cholecalciferol 1.0 mg/kg + 17β-E2 (old OVX-Vit D3 1.0-17β-E2),
old OVX rats + cholecalciferol 2.5 mg/kg + 17β-E2 (old OVX-Vit D3 2.5-17β-E2),
old OVX rats + cholecalciferol 5.0 mg/kg + 17β-E2 (old OVX-Vit D3 5.0-17β-E2).
The treatment period for animals was 14 days, and at the end of the treatment period (1 h after the last dose of solvent, Vitamin D3 or 17β-E2), all animals were subjected to the EPM, LDT and the open field test. During testing sessions in all behavioral tests the control and experimental groups of rats were also given with solvent, Vitamin D3 or 17β-E2.
Elevated plus maze test
EPM is a commonly accepted as standard test of anxiety-like behavior and was used to assess an anxiety-like behavioral responses [32, 33]. This test is sensitive to putative anxiogenic-like and anxiolytic-like drugs . The EPM is consisted of two open arms (50 × 10 cm2) and two closed arms (40 × 10 cm2) with a central platform (10 × 10 cm2), and elevated 50 cm above the floor level. All female rats from control and experimental groups were randomly placed at the center of the EPM and allowed them to freely move in the apparatus for 5 min. The number of entries and total time spent in open arms were accepted as parameters of anxiolytic-like effects of treatments. The apparatus was cleaned with damp cloth after each trial to avoid place preference and the influence of olfactory stimuli.
The apparatus was consisted of two identical boxes (30 × 40 × 40 cm), one of which with white walls and floor and illuminated by a 60 W light from above, while the other of the box was painted black and had a lid so it was not illuminated [35, 36]. The number of entrances and the total time in the light box were registered for 5 min . The increase of the number of entrances and the total time in the light box were postulated as manifestation of anxiolytic-like effects of treatments. The apparatus was cleaned with damp cloth after each trial to avoid place preference and the influence of olfactory stimuli.
Open field test
The effect of cholecalciferol on locomotor, rearing and grooming activities was evaluated automatically using an open-field computer-aided controlling system as described previously . The apparatus consists a square platform (80.0 cm × 80.0 cm; wall height 36.0 cm). The floor of the platform was divided into 16 equal squares of 19.5 cm × 19.5 cm. A video camera fixed at the top, and the apparatus was illuminated by a light source of 120 Lux on the ceiling. Each rat was placed at the center of the apparatus and allowed to explore freely for 5 min. Total number of central and peripheral square crossings were recorded for each animal. The apparatus was cleaned with damp cloth after each trial to avoid place preference and the influence of olfactory stimuli.
Determination of estradiol, 25-OH-VD3 and calcium levels in the blood serum
Blood samples were collected in tubes and centrifuged. After centrifugation, serum was separated, frozen and stored at − 20 °C until biochemical assessment. Estradiol levels was assessed using commercial available ELISA kit (DRG Diagnostics, Marburg, Germany). The sensitivity for estradiol detection using ELISA kit was 3.0 pg/ml. Measurement of 25-hydroxyvitamin D3 (25-OH-VD3) levels was performed by ELISA kit (CSB-E08098r, Cusabio Biotech Co., Ltd., Wuhan, P.R. China). Technical variability for 25-OH-VD3 ELISA kit was low with coefficients of variation of < 10% intra-assay and < 15% inter-assay. Detection range of 25-OH-VD3 levels was 20 μg/L-100 μg/L. The sensitivity of the 25-OH-VD3 ELISA kit was 5.0 μg/L. Calcium concentrations were detected by spectrophotometric method using Calcium assay colorimetric kit (ab102505, Abcam, France). The sensitivity of the calcium kit was 0.1 m/M. All the procedures of estradiol, 25-OH-VD3 and calcium kits were conducted following the manufacturer’s instruction manual.
Data were expressed as means ± standard error (S.E.M). Differences among means were postulated as significant at р ≤ 0.05. Behavioral and biochemical data were analyzed using a two-way ANOVA and subsequent post hoc analysis with Dunnett’s multiple comparison test. Statistical calculation was carried out using SPSS software 19 version (SPSS Inc., Chicago, IL., USA).
Vitamin D3 in different doses decreases anxiety-like profile of the old OVX and OVX rats given with 17β-estradiol after long-term absence of estrogen as measured in the EPM test
Two-way ANOVA test demonstrated a significant hormone condition × treatment interaction ([F(5,44) = 11.44, P < 0.05] and [F(5,44) = 11.12, p < 0.01], respectively), significant effect of hormone conditions ([F(5,44) = 9.22, P < 0.01] and [F(5,44) = 16.88, p < 0.01], respectively) and significant effect for treatment ([F(5,44) = 11.56, P < 0.05], and [F(5,44) = 12.56, p < 0.05], respectively) for the time spent into the open arms or the number of entries into the open arms of the old OVX rats. Post-hoc analyses revealed differences among the groups for the anxiety-like state during experimental sessions (p < 0.05).
Vitamin D3 supplementation administered in all doses to the old OVX rats resulted in increase of the time spent into the open arms and the number of entries into the open arms as compared to the old OVX rats treated with solvent (Fig. 1ab, p > 0.05). Combined administration of cholecalciferol at dose of 1.0 mg/kg with 17β-E2 to the old OVX rats more significantly increased the time spent into the open arms and the number of entries into the open arms as compared to the old OVX rats treated with solvent or 17β-E2 (Fig. 1ab, p > 0.05). The old OVX rats administered with cholecalciferol at doses of 2.5 mg/kg and 5.0 mg/kg plus 17β-E2 showed similar values of the time spent into the open arms and the number of entries into the open arms like as old OVX rats treated with 17β-E2 (Fig. 1ab, p > 0.05).
Vitamin D3 at different doses reverses anxiety-like profile of the old OVX and OVX rats given with 17β-estradiol after long-term absence of estrogen as measured in light-dark box
Two-way analysis of variance showed a significant hormone condition × treatment interaction ([F(5,44) = 11.52, p < 0.01]), significant effect of hormone conditions ([F(5,44) = 11.22, p < 0.05]) and significant effect for treatment ([F(5,44) = 10.08, p < 0.01]) for time spent and number of entries in the light compartment of the old OVX rats. Post-hoc analyses revealed differences among the groups for the anxiety-like state during experimental sessions (p < 0.05).
Vitamin D3 supplementation administered in all doses to the old OVX rats induced increase of the time spent and number of entries in the light compartment as compared to the old OVX rats treated with solvent (Fig. 2ab, p > 0.05). Combined administration of cholecalciferol at dose of 1.0 mg/kg with 17β-E2 to the old OVX rats more significantly increased time spent and number of entries in the light compartment as compared to the old OVX rats treated with solvent or 17β-E2 (Fig. 2ab, p > 0.05). The old OVX rats administered with Vitamin D3 at doses of 2.5 mg/kg and 5.0 mg/kg plus 17β-E2 showed identical parameters of time spent and number of entries in the light compartment like as old OVX rats treated with 17β-E2 (Fig. 2ab, p > 0.05).
Vitamin D3 administration changes behavioral reactivity of the old OVX and OVX rats treated with 17β-estradiol
Accordingly to the two-way ANOVA test, there were significant differences for the grooming behavior between hormone conditions ([F(5,44) = 8.12, p < 0.05]) between drug treatment ([F(5,44) = 12.51, p < 0.01]) and an interaction between hormone condition and treatments ([F(5,44) = 7.16, p < 0.01]) in the old OVX rats. Further post-hoc test revealed differences for grooming between experimental groups of the old OVX rats (p < 0.05).
Effects of Vitamin D3 administration on behavior of the old ovariectomized (OVX) rats following long-term estrogen deficiency in the open field test for 5 min
Old control rats + solvent
69.7 ± 5.2
11.5 ± 0.3
2.9 ± 0.2
Old intact rats + cholecalciferol 1.0 mg/kg
71.8 ± 2.9
10.7 ± 0.3
3.2 ± 0.2
Old intact rats + cholecalciferol 2.5 mg/kg
66.9 ± 3.6
10.4 ± 0.2
3.1 ± 0.2
Old intact rats + cholecalciferol 5.0 mg/kg
69.0 ± 4.2
12.2 ± 0.8
3.0 ± 0.2
Old OVX rats + solvent (OVX/solvent rats)
72.1 ± 2.3
12.1 ± 0.6
1.0 ± 0.2*
Old OVX rats +17β-E2 (OVX/17β-E2 rats)
64.3 ± 4.6
11.7 ± 0.8
3.1 ± 0.3#
Old OVX rats + cholecalciferol 1.0 mg/kg
63.2 ± 3.5
12.6 ± 0.9
4.2 ± 0.2#
Old OVX rats + cholecalciferol 2.5 mg/kg
67.2 ± 5.2
10.2 ± 0.8
3.9 ± 0.2#
Old OVX rats + cholecalciferol 5.0 mg/kg
70.3 ± 4.4
11.5 ± 0.5
4.3 ± 0.2#
Old OVX rats + cholecalciferol 1.0 mg/kg + 17β-E2
72.1 ± 6.8
12.2 ± 0.6
0.7 ± 0.2* # $
Old OVX rats + cholecalciferol 2.5 mg/kg + 17β-E2
78.5 ± 8.4
11.8 ± 0.4
0.6 ± 0.2* # $
Old OVX rats + cholecalciferol 5.0 mg/kg + 17β-E2
69.4 ± 6.6
10.9 ± 0.8
0.9 ± 0.2* # $
A significant decrease of grooming behavior was registered in the old OVX rats given with solvent as compared to the control (Table 1, p < 0.05). 17β-E2 significantly reduced grooming reactions in the old OVX rats as compared to the middle-aged OVX rats (Table 1, p < 0.05). The old OVX rats treated with Vitamin D3 in all tested doses alone or in a combination with 17β-E2 did not demonstrate any modifications of motor and rearing activities as compared to the OVX rats given with solvent (Table 1, p < 0.05).
However, the old OVX rats treated with Vitamin D3 at doses of 1.0, 2.5 and 5.0 mg/kg demonstrated an increase of grooming behavior as compared to the OVX rats. A co-administration of Vitamin D3 at these doses with 17β-E2 decreased grooming behavior as compared to old intact and OVX rats received with solvent or 17β-E2 (Table 1, p < 0.05).
Modifications of 25-hydroxyvitamin D3, estradiol and calcium levels in the blood serum following Vitamin D3 administration in the old OVX and OVX females treated with 17β-estradiol
The old OVX rats treated with cholecalciferol at all doses significantly increased 25-OH-VD3 and estradiol levels in the serum blood as compared to the old OVX rats treated with solvent (Fig. 4, p < 0.05). However, the values of 25-OH-VD3 and estradiol levels in the old OVX rats treated with cholecalciferol at all doses were lower than that of the values of old control rats.
Co-administration of Vitamin D3 (1.0 mg/kg) and 17β-E2 markedly enhanced estradiol levels in the old OVX rats as compared to the groups of old OVX rats received with solvent or 17β-E2 (Fig. 3, p < 0.05). Vitamin D3 supplementation (2.5 mg/kg and 5.0 mg/kg) plus 17β-E2 did not modify estradiol concentrations in the serum blood of the old OVX rats as compared to the OVX rats given with 17β-E2 (Fig. 3, p > 0.05). Cholecalciferol at all doses in combination with 17β-E2 significantly increased 25-OH-VD3 levels when these old OVX rats were compared with the old OVX/solvent and OVX/17β-E2 groups (Fig. 4, p > 0.05).
In the present study, the effects of chronic cholecalciferol treatment at different doses (1.0, 2.5 and 5.0 mg/kg, s.c.) for 14 days on anxiety-like behavior in the old female rats with long-term estrogen deficiency and 17β-E2 supplementation in a low dose were examined. Cholecalciferol at all investigated doses did not produce any changes of anxiety-like behavior of the old intact female rats in the EPM and LDT. Analyzing the results from biochemical assay, an increase of 25-OH-VD3 concentrations and absence of any modifications of estradiol levels in the serum blood of the middle-aged and old intact rats given with different doses of cholecalciferol were found.
These results suggest that cholecalciferol-induced the increasing of 25-OH-VD3 levels in the blood serum of the old intact-ovary rats are not associated with absence of anxiety-like profile alterations in the behavioral tests. Furthermore, the old ovary-intact female rats are also needed to evaluate the behavioral effects of cholecalciferol administered at several doses in the EPM and LDT paradigms.
The results showed that in the old OVX rats following 12 weeks of postovariectomy period, there were marked anxiety-like behavior as assessed by EPM and LDT. Although 17β-E2 supplementation resulted in significant anxiolytic-like effect of the old OVX rats with long-term absence of estrogen, the 17β-E2 administration was not able to completely diminish anxiety-like behavior to the level of the old control intact animals. According to these results, we conclude that old OVX rats following 12 weeks of postovariectomy period display significant anxiety-related behavior, while 17β-E2 administration to the old OVX rats attenuates the estrogen deficiency-induced anxiety-like behavior to some extent. In fact, these experiments showed that the effects of 17β-E2 supplementation on anxiety-like behavior did not associated with absence of its effects on 25-OH-VD3 levels in the old OVX rats. The long-term effect of ovariectomy on anxiety-like behavior in old female rats were submitted in a standard behavioral tests [26, 27, 38].
Cholecalciferol at all doses per se had a significant anxiolytic-like effect in the old OVX rats following long-term ovariectomy. Unexpectedly, that the old OVX rats with 12 weeks postovariectomy period administered with cholecalciferol at doses 2.5 and 5.0 mg/kg/day in combination with 17β-E2 showed similar anxiety-like profile like the OVX rats given with 17β-E2. Thus, we did not observe any synergic anxiolytic-like effects of cholecalciferol at doses of 2.5 mg/kg or 5.0 mg/kg in the old OVX rats given with 17β-E2. It might supposed that there are some concurrent relation between 17β-E2 and cholecalciferol at doses of 2.5 and 5.0 mg/kg/day. In fact, application of 17β-E2 interfere with anxiolytic-like action of cholecalciferol at doses of 2.5 mg/kg or 5.0 mg/kg in the old OVX rats after long-term ovariectomy. Simultaneously, cholecalciferol treatment in all tested doses similarly increased grooming, did not change locomotor activity and rearing of the old OVX rats after long-term ovariectomy. Thus, the present results suggest that anxiolytic-like effects of Vitamin D3 are specific in the old OVX rats given with solvent or 17β-E2, since data of the OFT were not able to demonstrate any of alterations in motor or rearing activities in these rats.
Biochemical analysis showed that administration of cholecalciferol at all doses alone or in a combination with 17β-E2 resulted in elevated 25-OH-VD3 levels in the blood serum of the old OVX rats with long-term absence of estrogen. Cholecalciferol administered alone at all doses similarly increased estradiol levels in the blood serum of the old OVX rats after long-term ovariectomy. On the other hand, only application of cholecalciferol at a dose of 1.0 mg/kg with low dose of 17β-E2 induced more profound increase of estradiol levels in the blood serum of the old OVX rats. Moreover, cholecalciferol in several doses failed to induce any changes in calcium concentrations in the blood serum of the old OVX rats given with solvent or 17β-E2.
These data suggested that the different effects of cholecalciferol application per se in the old OVX rats with long-term absence of estrogen on anxiety-like behavior in the EPM and LDT did not associated with its effects on estradiol, 25-OH-VD3 and calcium levels.
However, we can speculate that behavioral effects of cholecalciferol treatment with low dose of 17β-E2 in the EPM and LDT tests might connected with fluctuations of estradiol levels in the blood serum of the old OVX rats. It is possible that specific sites of action involved in the anxiolytic-like effects of cholecalciferol that also modulated by estrogens are affected by the endocrine milieu that prevails at different period for the old female rats. Moreover, after a long-time absence of ovarian fluctuations an adaptive process may contribute to a better response for cholecalciferol administration at a dose of 1.0 mg/kg in the old female rats.
The role of ovarian hormones in anxiety and stress sensitivity is of great interest for women transitioning through menopause [39, 40]. Mood disorders during menopause could be partly due to loss of estrogen with menopause because estrogen is known to have neuroprotective effects on brain [41, 42]. Menopausal hormonal therapy (MHT) may improve the symptoms of affective-related state in people or decrease the risk of developing mood disturbances in older women, but this is unclear because in some studies MHT does not stop the development of anxiety-like symptoms in elderly postmenopausal women . The exact role of estrogen still needs to be defined.
Menopause are also at higher risk of developing VD deficiency due to decreased dietary intake, less sun exposure, restricted outdoor activity and a decreased capacity to produce enough calcitriol as a result of an age related decline in hydroxylation by kidneys [44, 45, 46].
Vitamin D3 is a hormone precursor which is transformed into 1,25-dihydroxyvitamin D (1,25-(OH)2D3) in the liver and kidney . Through decades This active form of VD has been involved in the brain development and functions of the central nervous system (CNS) [48, 49]. Hormonal form 1,25(OH)2D3 enters the brain via the blood brain barrier to act directly on cells containing its nuclear receptor, the VDR [50, 51].
The presence of VD receptors (VDR) outside the skeletal system, enterocytes and renal tubular cells was confirmed in many cell types including immune cells, neurons, pancreatic cells, myocytes, cardiomyocytes, endothelium cells, which stress pleiotropic activity of VD [52, 53]. The active form of vitamin D is transferred to astrocytes where it can bind to VDR and initiate gene transcription or be inactivated when in excess [50, 51]. Alternatively, 1,25(OH)2D3 can induce autocrine or paracrine rapid non-genomic actions since all brain cell types express the other membrane receptor of VD . It is possible that the behavioral effects of cholecalciferol are mediated by multiple target regions, including brain centers that are involved in the mechanisms of anxiety-like behavior. Regardless, it cannot presently exclude possible indirect effects of vitamin D3 on different neurotransmitter circuits. Further research is required to investigate the underlying mechanisms in its anxiolytic-like effects.
It is well-established both systemic effects of VD on calcium metabolism and neuroprotective effects of VD on the brain . Low VD levels has been implicated in the pathophysiological mechanisms of cardiovascular diseases, depression, anxiety, cognitive disorders, obesity, metabolic syndrome, type 2 diabetes, various types of cancer, immune disorders [10, 54]. According to Gaugris and co-workers (2005) , the prevalence of low VD levels appears to be high in postmenopausal women. Additionally, the decline of estrogens after menopause decreases the activity of 1α-OHase, what results in lower synthesis of the active VD form [55, 56]. Application of Vitamin D3 in specific periods of women’s life, seems to be of great importance, because it may reduce the risk of affective-related diseases during menopausal period [57, 58, 59]. However, the current data for Vitamin D3 application studies are very incomplete and need of more intensive investigations. The main point of question is to examine how the interaction between Vitamin D3 and estradiol might alter at specific periods of women’s life, and the impacts of such alterations elsewhere in the postmenopausal woman. VDR have been identified throughout the female reproductive tract [60, 61]. Some studies have demonstrated a direct modulation by VD of estradiol, estrone, and progesterone production in human ovarian cells [62, 63, 64]. It could be supposed that estrogens and VD share similar targets of the brain to induce their anxiolytic-like effects. However, the behavioral manifestations of VD at various doses are completely different in the middle-aged and old OVX females. It is likely that VD acts through a various mechanisms that are sensitive in female rats of old age with long-term absence of ovarian hormones. Moreover, it is completely needed to understand the precise mechanisms of how VD treatment alone or in a combination with 17β-estradiol supplementation may affect women’s anxiety-related state.
These points illustrate how the current state of VD treatment research is incomplete and in need of more intensive research. Working toward uncovering how the interaction between VD and estradiol changes after menopause, and the implications of these changes elsewhere in the postmenopausal woman, is necessary for providing the most complete understanding of how VD treatment alone or in a combination with 17β-estradiol supplementation may affect women’s affective-related state.
VD as changes in VDR impact on various brain neurotransmitters, and thus suggest a potential role of vitamin D in causing and redressing mood disorders . It could be supposed, even though estrogens and cholecalciferol share similar targets on monoaminergic or another neurotransmitter systems to induce their anxiolytic-like effects, the behavioral manifestations of cholecalciferol are completely different in the old OVX females. It is likely that cholecalciferol acts through a different mechanisms of action that is sensitive to the age of female rats with long-term absence of ovarian hormones.
In conclusion, the results of this study can be summarized as follows: all tested doses of cholecalciferol given alone are produced anxiolytic-like effects in the EPM and LDT in the old OVX female rats; the one specific dose of cholecalciferol (1.0 mg/kg/day) in the old OVX rats is able to induce synergic anxiolytic-like effect in the EPM and LDT; effects of cholecalciferol on anxiety-like behavior in the old OVX rats after long-term absence of estrogen are dependent from absence or presence of additional hormonal treatment as 17β-E2. Further investigations is to be addressed in relation to such issues: whether different effects of cholecalciferol on anxiety-like behavior are dependent from different age of rats, or whether different doses of cholecalciferol on anxiety-like behavior in OVX rats with different age rats might lead to negative versus positive effects. Further research, with properly designed experimental studies, is needed to test this hypothesis. In addition, further research is needed to elucidate the biochemical mechanism/(s) of cholecalciferol effects on the anxiety-like behavior and their physiological relevance for development of mood impairment at estrogen deficiency at aging. Furthermore, the mechanism by which cholecalciferol produces anxiolytic-like effect in the old OVX rats and the implications of this in brain function need to be investigated in future research. Moreover, further studies are needed to evaluate the association of VD with estrogen-related pathways and to conduct detail experiments together with biochemical studies of these subjects to verify the significance of this study.
The present data of the preclinical study indicates that chronic cholecalciferol at a dose of 1.0 mg/kg, s.c. treatment decreased anxiety-related behavior after impairment induced by long-term ovariectomy in the old female rats with long-term absence of estrogen. Moreover, a combination of cholecalciferol at a dose of 1.0 mg/kg s.c. and 17β-E2 is more effective than 17β-E2 alone in the old OVX rats inducing a more synergic anxiolytic-like effects in the EPM and LDT. Furthermore, this is the first study to show a beneficial effect of chronic cholecalciferol at dose of 1.0 mg/kg s.c. administration on anxiety-related states induced by long-term ovariectomy in the old female rats. Importantly, these results suggest that 17β-E2 administration interfered with anxiolytic-like action of cholecalciferol administered alone at doses of 2.5 mg/kg or 5.0 mg/kg to the old OVX rats with long-term absence of estrogens. This work promotes more effective creating of the novel therapeutic targets and strategies for anxiety-like treatment in the old subjects with long-term estrogen deficiency.
This work was financially supported by Government of Russian Federation, Grant 08–08. The funding body played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript. Publication costs are funded by the author.
Availability of data and materials
About this supplement
This article has been published as part of BMC Medical Genetics Volume 20 Supplement 1, 2019: Selected articles from BGRS\SB-2018: medical genetics. The full contents of the supplement are available online at https://bmcmedgenet.biomedcentral.com/articles/supplements/volume-20-supplement-1.
Author JOF designed the study, performed the experiments, analyzed the data and wrote the protocol and manuscript. The author read and approved the final manuscript.
All the experiments performed this research were approved by the Ethical Committee for Animal Research, I.P. Pavlov Institute of Physiology of the Russian Academy of Sciences (protocol 1095/1 from June 25, 2012). The field experiments were conducted under local legislation and permissions.
Consent for publication
The author declares that she has no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 4.Maki PM, Freeman EW, Greendale GA, Henderson VW, Newhouse PA, Schmidt PJ, et al. Summary of the National Institute on aging-sponsored conference on depressive symptoms and cognitive complaints in the menopausal transition. Menopause. 2010;17:815–22. https://doi.org/10.1097/gme.0b013e3181d763d2.CrossRefPubMedPubMedCentralGoogle Scholar
- 10.Pae CU, Mandelli L, Kim TS, Han C, Masand PS, Marks DM, et al. Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. Biomed Pharmacother. 2009;63:228–35. https://doi.org/10.1016/j.biopha.2008.03.010.CrossRefPubMedGoogle Scholar
- 11.Vedder LC, Bredemann TM, McMahon LL. Estradiol replacement extends the window of opportunity for hippocampal function. Neurobiol Aging. 2014;35:2183–92. https://doi.org/10.1016/j.neurobiolaging.2014.04.004.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Zabodalova L, Ishchenko T, Skvortcova N, Baranenko D, Chernjavskij V. Liposomal beta-carotene as a functional additive in dairy products. Agron Res. 2014;12(3):825–34.Google Scholar
- 19.Groves NJ, McGrath JJ, Burne TH. Vitamin D as a neurosteroid affecting the developing and adult brain. Annu Rev Nutr. 2014;34:117–41. https://doi.org/10.1146/annurev-nutr-071813-105557.CrossRefPubMedGoogle Scholar
- 28.Bosee R, Di Paolo T. Dopamine and GABAA receptor imbalance after ovariectomy in rats: model of menopause. J Psychiatry Neurosci. 1995;20:364–71.Google Scholar
- 32.Pellow S, File SE. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol Biochem Behav. 1986;24:526–30.Google Scholar
- 37.Fedotova J, Soultanov V, Nikitina T, Roschin V, Ordayn N. Ropren® is a polyprenol preparation from coniferous plants that ameliorates cognitive deficiency in a rat model of beta-amyloid peptide-(25–35)-induced amnesia. Phytomedicine. 2012;19:451–6. https://doi.org/10.1016/j.phymed.2011.09.073.CrossRefPubMedGoogle Scholar
- 58.Kalueff AV, Eremin K, Tuohimaa P. Mechanisms of neuroprotective action of vitamin D3. Biochem. 2004;69:738–41.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.